Compare AAT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | HROW |
|---|---|---|
| Founded | 1967 | 1998 |
| Country | United States | United States |
| Employees | 208 | 373 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2010 | N/A |
| Metric | AAT | HROW |
|---|---|---|
| Price | $25.31 | $42.30 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $19.50 | ★ $69.86 |
| AVG Volume (30 Days) | 455.3K | ★ 836.4K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $436,204,000.00 | N/A |
| Revenue This Year | $4.33 | $31.62 |
| Revenue Next Year | $0.22 | $50.77 |
| P/E Ratio | $315.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.72 | $28.54 |
| 52 Week High | $25.34 | $54.98 |
| Indicator | AAT | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 70.84 | 62.53 |
| Support Level | $18.23 | $40.61 |
| Resistance Level | N/A | $44.50 |
| Average True Range (ATR) | 0.49 | 2.09 |
| MACD | -0.02 | 0.21 |
| Stochastic Oscillator | 88.95 | 64.24 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.